Gemcitabine as single agent therapy in advanced non small cell lung cancer and quality of life in the elderly

Panminerva Medica

Volumn 43, Issue 1, 2001, Pages 15-19

  Bianco, V ^a,b   Di Girolamo, B ^a   Pignatelli, E ^a   Speranza, I ^a   Florio, G ^a   Gemma, D ^a   Girolami, M ^a   Vietri, F ^a   Marchei, P ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE   (Italy)

Author keywords

Aged; Anti metabolites, antineoplastic therapeutic use; Carcinoma, non small cell lung; Deoxycytidine analogs and derivatives; Quality of life

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE;

AGED; ARTICLE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; QUALITY OF LIFE;

EID: 0035287869     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Caruso V, Bianco V, Cumbo A, Anselmi D, Ascoli A, Marchetti A et al. Valutazione dei fattori di rischio, diagnosi e trattamento del carcinoma del polmone nei pazienti anziani. Riv Tuberc Mal App Resp Fs 1997;4-211-7.
2. Caruso V, Bianco V, Corsonello F, Giunta S, Riondino C. Il cancro negli anziani: considerazioni clinico-epidemiologiche. Minerva Med 1997;83:81-6.
3. Ihide DC. Chemotherapy of lung cancer. N Engl J Med 1991;327(12):1434-41.
4. Grilli R, Oxman AD, Julien JA. Chemotherapy for advanced of non-small cell lung cancer: how much benefit is enough. J Clin Oncol 1993;11:1886-72.
5. Cartei G, Cartei F, Cantone A, Causarano D, Genco G, Tobaldin A et al. Cisplatin-Cyclophosfamide-Mitomycin combination chemiotherapy with supportive care vs supportive care alone for treatment of metastatic non-small cell lung cancer. J Natl Cancer Inst 1993;85:794-800.
6. Le Chevalier T, Brisgand D, Douillard J, Pujol JL, Alberola V, Monnier A et al. Randomized study of vinorelbine and cisplatin vs vindesine and cisplatin vs vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360-7.
7. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA. Polychemotherapy in advanced non small cell lung cancer: a meta analysis. Lancet 1993;342:19-21.
8. Rinaldi M. Correlation between age and prognosis in patients with advanced non small cell lung cancer treated with cisplatin containing chemotherapy: a retrospettive multicenter study. Proc ESMO Ann Oncol 1994;5(Suppl 8):58,289.
9. Rapp E, Pater JL, Willian A, Cormier Y, Murray N, Evans WK. Chemotherapy can prolong survival in patients with advanced non small cell lung cancer. Report of Canadian multicenter randomized trial. J Clin Oncol 1988;6:633-41.
10. Plunken W, Huang P, Zheng Xu Y, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanism of action and self potention. Semin Oncol 1995;22:3-10.
11. Csoka K, Liliemark J, Larsson R, Nygren P. Evolution of the cytotoxit activity of gemcitabine in primary cultures of the tumor cell from patients with hematologic or solid tumors. Semin Oncol 1995;22(Suppl 11):47-53.
12. Le Chevalier T. Single agent activity of gemcitabine in advanced non small cell lung cancer. Semin Oncol 1996;23(Suppl 10):36-42.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
14. Spitzer W, Dobson A, Hall J. Measuring the quality of life of cancer patients. J Chron Dis 1981;34:585-98.
15. Lewton MP, Brody EM. Assessment of older people: self mainteinig and instrumental activity of daily living. Gerontologist 1969;9: 179-84.
16. Bergaman B, Aaronson NK, Abemedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a moduler supplement to the EORTC care quality of life questionnaire (QLQ C30) for use in lung cancer clinical trials. Eur J Cancer 1994;5:635-42.
17. Abratt R, Bezwoda W, Falkson G, Goedhais L, Hacking D. Efficacy and safety of gemcitabine in non small cell lung cancer: phase II study results. Ann Oncol 1992;3(Suppl 5): 198.
18. Le Chevalier T, Gottfriend M, Gatzemeier U, Shepherd F, Weynants P, Cottier B et al. A phase II multicenter study of gemcitabine in non small cell lung cancer. Bull Cancer 1997;84:282-8.
19. Yokoama A, Nakai Y, Yoneda S, Kurita Y, Niitani H. Activity of gemcitabine in the treatment of patients with non small cell lung cancer: a multicenter phase II study. Anticancer Drugs 1997;8: 574-81.
20. Takada M, Negoro S, Kudo S, Furuse K, Nishikawa H, Takada Y. Activity of gemcitabine in non small cell lung cancer: results of the Japan gemcitabine group (A) phase II study. Cancer Chemother Pharmacol 1998;41:217-22.
21. Cumbo A, Bianco V, Gianni W, Pasqua F, Mazzei V, Visconti L et al. Monochemioterapia con gemcitabina del cancro polmonare NSCLC. Congresso nazionale «Tumori in età geriatrica», 1-3 dicembre 1997. Roma: Ed. Verduci, 1997.
22. Halme M, Jekunen A, Tamminen K, Mattson K. Phase II study of weekly gemcitabine in advanced non small cell lung cancer. Respir Med 1997;91:423-6.
23. Fossella FV, Lippman SM, Shin DM, Tarassoff P, Calayal-Jung M, Perez-Soler R. Maximum tolerated dose defined for single agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non small cell lung cancer. J Clin Oncol 1997;15:310-6.
24. Anderson H, Lund B, Bach F, Thatcher T, Welling J, Hansen HH. Single agent activity of weekly gemcitabine in advanced non small cell lung cancer: a phase II study. J Clin Oncol 1994;12:1821-6.
25. Salvati F, Antilli A, Cruciani AR, Lombardi A, Mugnaini L, Nunziati F. Lonidamine plus cyclophosphamide in the treatment of advanced non small cell lung cancer in the elderly: a phase II study. Tumori 1995;81:48-51.
26. Gallotti P, Chiesa E, Olgiati A, Natale G, Bottaro G, Freddi E. Vindesine as monochemotherapy in non small cell lung cancer (NSCLC) in elderly patients. Ann Oncol 1992;36:3(Suppl 5): 1992.
27. Colleoni M, Gaion F, Nelli P, Colmellere GM, Manente P. Weekly vinorelbine in elderly patients with non small cell lung cancer. Tumori 1994;80:448-52.
28. Baldini E, Tibaldi C, Pfanner E. Phase II study of oral doxifluoridine in elderly patients with advanced non small cell lung cancer. Am J Clin Oncol 1996;19:592-4.
29. Gridelli C, Perrone F, Gallo C, De Marinis F, Ianniello G, Cigolari S. Vinorelbine is well tolerated and active in the treatment on elderly patients with advanced non small cell lung cancer. A two-stage phase II study. Eur J Cancer 1997;33:392-7.
30. Veronesi A, Crivellari D, Magri MD, Cartei G, Mansutti M, Foladore S. Vinorelbine treatment of advanced non small cell lung cancer with special emphasis on elderly patients. Eur J Cancer 1996; 32A: 1809-11.